The first imitation of modafinil -- Wilman's "great" is on the market

Source: Medical Economic News December 15, 2017 Recently, modafinil (trade name "great"), a new central nervous stimulant developed by Wellman Pharmaceutical Co., Ltd in Northern Hunan Province, has obtained the production approval from CFDA It is believed that it will not be long before tens of thousands of patients with obstructive sleep apnea syndrome (OSA) suffer from mental retardation, memory loss, inattention, drowsiness and other problems People with poor test scores and jet lag will have a spring of medicine, especially the traffic accident rate caused by driver fatigue can be reduced by about 70%, and it is possible for soldiers to fight tirelessly for 72 hours The current situation of sleep related diseases is worrisome About one-third of people's life is spent in sleep, and sleep is for better waking up Lack of sleep and decreased alertness after waking up not only affect personal health, but also easily lead to military, industrial, public communications and many other major emergencies Challenger crash, Chernobyl nuclear power plant explosion and other events are closely related to the sleep disorders of the parties concerned According to the survey, 38% of all traffic accidents in the United States are related to sleep disorders; in malignant traffic accidents, the proportion is as high as 87% There are 2 million traffic accidents every year in China, and the death toll is up to about 100000 However, there is no detailed investigation in this area in China Most traffic accidents are only attributed to fatigue driving, in fact, many of them are related to sleep disorders On May 25, 2016, at the "Peking University - University of Pennsylvania International Sleep Medicine Forum", more than 20 experts from the United States and China gathered with 300 domestic doctors in the field of sleep medicine to discuss sleep and occupational safety and work efficiency At the forum, Peking University and the University of Pennsylvania jointly released the 2016 white paper on sleep and occupational safety (hereinafter referred to as the "white paper on sleep") By introducing the common causes of daytime sleepiness - obstructive sleep apnea, insomnia, shift work and narcolepsy, this paper reveals the harm of sleep diseases to people's health, daily life and work, and focuses on sleep The low rate of disease treatment calls for people to pay attention to sleep diseases and timely diagnosis and treatment According to the sleep white paper, obstructive sleep apnea (OSA) is a common cause of daytime sleepiness It is a systemic disease as well as a common disease It is mainly manifested in snoring at night, disappearance or restriction of respiratory air flow, resulting in intermittent hypoxia Hypoxia causes frequent awakening and sleep fragmentation Therefore, daytime sleepiness may occur, involving multiple organs and systems such as respiration, circulation and metabolism In the United States, about 26% of adults have different degrees of OSA, while the prevalence of OSA among employees is 34% in men and 17% in women China's epidemiological survey shows that 20.4% of adults suffer from OSA The study found that OSA affects patients' health, work efficiency and academic test scores In addition, OSA can be associated with cardiovascular and cerebrovascular diseases, metabolic diseases and Alzheimer's disease According to the sleep white paper, OSA can be effectively treated At present, modafinil combined with continuous positive airway pressure (CPAP) is the classic method to treat OSA in Europe and America After treatment, the symptoms of patients can be improved and the quality of life can be significantly improved In this way, it can reduce the incidence of traffic accidents, reduce the investment of medical insurance, improve work efficiency and overall productivity According to the sleep white paper, 80% of potential OSA patients have not been diagnosed and treated in time Among them, the lack of public awareness of OSA, the complexity of existing diagnostic methods, the limited sleep centers and sleep doctors, the low compliance of CPAP treatment, and the lack of a safe and effective neurostimulant approved for marketing are the important reasons for the low diagnosis and treatment rate In particular, China had no drugs to treat before, and now CFDA has approved the exclusive listing of Welman's "great" modafinil In addition, insomnia, shift work, long-term staying up late, jet lag, playing mahjong all night, long-term fatigue driving and so on will lead to the decline of people's work efficiency, memory decline, the increase of the probability of making mistakes, poor performance in learning and examination, and the decline of overall productivity; the risk of traffic accidents of the insomnia population is also higher than that of the general population Therefore, people should pay more attention to the above sleep diseases Modafinil is a new central stimulant developed by Lafon laboratory in France It has been listed in Europe, America and Japan The special topic of people's daily, transnational cooperation on intellectual property rights between Chinese and American enterprises, for a better future for mankind, reported that Wilman in Northern Hunan had captured the bright prospect of modafinil as early as 1995, and had actively carried out long-term transnational cooperation on international new drug modafinil with famous pharmaceutical and Biotechnology Enterprises in the United States since 1997 After ten years of research, he took the lead in obtaining the clinical research approval of modafinil in China in 2004, and after more than ten years of painstaking, outstanding and effective research, analysis and summary, he continued to research and develop new uses, new intellectual property rights and new invention patents of modafinil, greatly improved the quality and reduced the side effects, and finally completed the clinical research of tablets, capsules and dispersible tablets 。 The most famous thing in modafini is that the US Operation Desert Storm defeated Iraq 72 hours in a row and captured Saddam Hussein alive In addition, the French air force used modafinil as an anti fatigue and central stimulant for pilots in the Gulf War In 1995, two anti sleeping drug experiments conducted jointly by France, the United States and Canada proved that modafinil, as an anti sleeping drug, has less side effects on human body and is superior to amphetamine, and has important military and other special application prospects (see the PLA Daily on January 31, 1996)   In 2016, Xu Yongjie, Liu Yingqi and He Wei, reporters of the PLA Daily, reported that modafinil can significantly enhance brain nerve activity and human body function, memory and willpower, boost spirit and improve mood, feeling, thinking and emotion, and even maintain 72 hours of continuous work without rest, And always keep clear mind, judgment, but also from the physiological effectively inhibit the generation of fear According to foreign media, the U.S military has successfully applied this research to combat, leading the new trend from civilian to military It has become a "secret weapon" for Air Force pilots, naval ship personnel, strategic transport personnel and night Raiders in extreme environments, which can enhance the attention, judgment, response and eliminate the fear of combat There are three advantages of modafinil: 1 Long acting preparation, once a day oral administration; 2 No addiction; 3 The only effective neurostimulant confirmed by randomized double-blind control study And as a refreshing drug, there is also the most striking point: the user does not need to pay "sleep debt", which means that the user does not sleep after taking the medicine the night before, and only needs to sleep for 8 hours the next day to make up for the sleep As a result, foresight, the UK government's think-tank, pointed out in 2007 that within 20 years, drugs such as modafinil would be "as popular as coffee"